Results 51 to 60 of about 38,272 (314)

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland [PDF]

, 2014
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA).
Dippel, Franz-Werner, Gasche, David, Lebioda, Andrea, Plantör, Stefan, Theobald, Karlheinz   +4 more
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice. [PDF]

, 2017
BACKGROUND AND PURPOSE: Hyperglycaemia increases glucose concentrations in airway surface liquid and increases the risk of pulmonary Pseudomonas aeruginosa infection.
Baines, DL, Baker, EH, Benjamin, A, Garnett, JP, Gill, S, Groves, H, Lundqvist, AJ, Orogo-Wenn, M, Smith, DM, Taylor, JD, Tregoning, JS, Walters, D, Wingren, C, Åstrand, A   +13 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

Journal of Diabetes Investigation, 2020
Aims/Introduction Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator ...
Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara   +5 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

BMC Medicine, 2022
Background Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyun-Ju Lee, Ro-kyung Moon, Yong-Joon Lee, Seung-Jun Lee, Oh-Hyun Lee, Choongki Kim, Jaewon Oh, Chan Joo Lee, Yong-ho Lee, Seil Park, Ok-Hee Jeon, Donghoon Choi, Geu-Ru Hong, Jung-Sun Kim   +16 more
doaj   +1 more source

Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. [PDF]

, 2019
学位記番号 ...
Shibusawa, Ryo, シブサワ, リョウ, 澁澤, 良   +2 more
core  

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice

Kidney & Blood Pressure Research
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors target SGLT2 in renal proximal tubules and promote glycosuria in type 2 diabetes mellitus in humans and animal models, resulting in reduced blood glucose levels.
Jin Joo Cha, Hye-jin Park, Ji Ae Yoo, Jungyeon Ghee, Dae Ryong Cha, Young Sun Kang   +5 more
doaj   +1 more source